ideasIdea
Bundled episode payments for cancer care with bonuses for guideline concordance
Pay hospitals a single amount for a whole course of cancer treatment, with extra for following the evidence, rather than paying per visit and per drug, which rewards fragmentation.
The US Oncology Care Model and its successor tested episode-based payment for chemotherapy episodes with quality measures; results on cost were mixed, but process measures improved. A design that ties a larger share of payment to guideline concordance, supportive care access, and avoidance of low-value end-of-life chemotherapy, while adjusting for case mix, could align incentives with coordination. This is a payer experiment, and needs careful attention to unintended effects.
Hypothesis
Episode payment with concordance bonuses will improve guideline-concordant care and reduce emergency visits and end-of-life chemotherapy without increasing total cost per episode.
Rationale
Fee-for-service rewards volume and fragmentation; bundles create a single accountable entity for the episode, which is the precondition for coordination.
What would test it
A randomised payer pilot across practices with concordance, utilisation, patient experience, and cost as endpoints, evaluated independently.
Maturity
being tested at scale
Who has to act
payer
Cost to try
Large (over $50M)
Years to first evidence
5
Bottlenecks it attacks
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.